enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Merck's Keytruda gets FDA nod for expanded use in lung cancer

   www.aol.com/news/mercks-keytruda-gets-u-fdas...

   (Reuters) -The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in early-stage patients with non-small cell lung cancer who ...

3. Merck stops testing combo drug for lung cancer - AOL

   www.aol.com/news/merck-stops-testing-combo-drug...

   The patients tested with a combination of its experimental drug, vibostolimab, with Keytruda experienced a higher rate of immune-related side effects, Merck said, adding that patients should stop ...

4. Pembrolizumab - Wikipedia

   en.wikipedia.org/wiki/Pembrolizumab

   Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 Inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...

5. Merck's lung cancer drug combo fails trial in setback for new ...

   www.aol.com/news/mercks-lung-cancer-drug-combo...

   Merck's experimental anti-TIGIT drug vibostolimab in combination with its approved therapy Keytruda also failed to improve overall survival in a study of patients with non-small-cell lung cancer ...

6. Merck Discontinues Certain Cancer Candidate Trials After ...

   www.aol.com/finance/merck-discontinues-certain...

   Vibostolimab is being evaluated as an investigational fixed-dose combination with Keytruda (pembrolizumab) in the KeyVibe program. ... Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe ...

7. Merck's Keytruda Improves 5-Year Survival in Lung Cancer - AOL

   www.aol.com/news/mercks-keytruda-improves-5...

   Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates

8. Merck scraps two late-stage trials of cancer drug Keytruda

   www.aol.com/news/merck-scraps-two-stage-trials...

   A trial of the drug in patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma was stopped for "futility", meaning it was likely to fail, the company said.

9. Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion - AOL

   www.aol.com/news/merck-gets-fda-nod-keytruda...

   Merck (MRK) gets FDA approval to include overall survival data from a key late-stage lung cancer study, KEYNOTE-189 study, on the label of its PD-L1 inhibitor, Keytruda.